TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

You Are Here: Home  »  Research Funding  »  Small Business  » 

Skip secondary menu

NINDS Announces New Programs to Support the Development of Neurotherapeutics

NINDS is announcing new programs to support the development of neurotherapeutics by academics and small businesses including the Blueprint Neurotherapeutics Program 2.0 for the CREATE program for biologics and devices. Both are designed to move new therapies from the bench to patients and not just to the bookshelf.

The Blueprint Neurotherapeutics Program 2.0 will support development of small molecule therapeutics by providing grant funding, as well as access to a collection of contract services and consultants with extensive industry experience in the areas of pharmacology, medicinal chemistry, pharmacokinetics, toxicology, GMP synthesis, formulation development, and Phase I clinical safety testing.

The Cooperative Research to Enable and Advance Translational Enterprises (CREATE) is a new program designed to support the development of both biologics/biotechnology and therapeutic device products. Funding opportunities for biologics and biotechnology products in the CREATE program will focus on the discovery of therapeutic biotechnology products and biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, and cell therapies). There will be two tracks, an earlier stage CREATE Bio Discovery Track and the later stage CREATE Bio Development Track that goes through to early clinical trials.

For CREATE devices there will be three tracks: 1. Translational and Clinical Studies to Inform Final Device Design, 2. Translational and Clinical Studies on the Path to 510(k), 3. Translational and Early Feasibility Studies on the Path to Pre-Market Approval (PMA) or Humanitarian Device Exemption (HDE).

In addition to funding opportunities, NINDS has an active portfolio of more than 100 grants and can provide information to potential investors. The portfolio includes small molecules, devices, and biologics for indications such as Alzheimer’s disease, Amyotrophic Lateral Sclerosis, Epilepsy, Glioma, Lyososomal Storage Disorder, Muscular Dystrophy, Multiple Sclerosis, Pain, Parkinson’s disease, Stroke, and Traumatic Brain Injury.

For additional information on NINDS opportunities in translational research, please visit:

Last Modified June 30, 2014